Clearmind Medicine Signs Exclusive Patent Licensing Agreement With Yissum Research Development Company Of The Hebrew University Of Jerusalem; Under Agreement, Co. Receives Exclusive Rights to Develop, Manufacture and Commercialize Compounds For Treating PTSD And Other Mental Health Disorders
Portfolio Pulse from Benzinga Newsdesk
Clearmind Medicine has signed an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. The agreement grants Clearmind exclusive rights to develop, manufacture, and commercialize compounds for treating PTSD and other mental health disorders.
June 20, 2024 | 11:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clearmind Medicine has obtained exclusive rights to develop, manufacture, and commercialize compounds for treating PTSD and other mental health disorders through a new agreement with Yissum Research Development Company.
The exclusive patent licensing agreement is a significant development for Clearmind Medicine, potentially expanding its product portfolio and market reach in the mental health sector. This could positively impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100